SCHEMBL1507074

SCHEMBL1507074

O=C1C=CC(=O)c2ncccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 7/20 1.00
CDC25B P30305 4/20 1.00
TDP2 O95551 3/20 0.58
NSD2 O96028 3/20 0.58
PAX8 Q06710 3/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
ABL1 P00519 1/20 0.58
PLCG1 P19174 1/20 0.58
CES1 P23141 1/20 0.58
RIN1 Q13671 1/20 0.58
THRB P10828 1/20 0.58
BLM P54132 1/20 0.58
GAA P10253 1/20 0.58
PADI1 Q9ULC6 2/20 0.53
PADI3 Q9ULW8 2/20 0.53
PADI4 Q9UM07 2/20 0.53
PADI2 Q9Y2J8 2/20 0.53
TGM2 P21980 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29747118 1.00 S100A4 (1.00) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL12231792 0.84 S100A4 (0.71) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL22013897 0.77 CDC25B (0.63) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL30646118 0.77 CDC25B (0.63) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL6212776 0.77 S100A4 (0.63) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL31747733 0.77 S100A4 (0.63) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL28803385 0.77 S100A4 (0.61) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL5915065 0.73 TDP2 (0.81) S100A4CDC25BTDP2NSD2PAX8
SCHEMBL460433 0.73 TDP2 (1.00) S100A4CDC25BTDP2NSD2PAX8
Phanquone SCHEMBL7633567 0.73 MEN1 (1.00) S100A4CDC25BTDP2NSD2PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4427812-A2 SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE The Regents of the University of Michigan (US) 2024-09-11 EP claimed
EP-3934634-B1 SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE UNIV MICHIGAN REGENTS (US) 2024-07-24 EP claimed
CN-108299415-B Quinolinequinone derivative and preparation method and application thereof 南通大学 2020-11-10 CN claimed
WO-2020055192-A2 PREPARATION METHOD FOR QUINOLINE-5, 8-DIONE DERIVATIVE WHICH IS TGASE 2 INHIBITOR 재단법인 대구경북첨단의료산업진흥재단 2020-03-19 WO claimed
EP-2257515-B1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NAT RECH SCIENT (FR) 2017-05-17 EP claimed
US-9096519-B2 Process for the synthesis of ketones from internal alkenes CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-08-04 US claimed
US-20140194604-A1 PROCESS FOR THE SYNTHESIS OF KETONES FROM INTERNAL ALKENES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2014-07-10 US claimed
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2013-04-11 US claimed
WO-2011146101-A1 CHEMICAL AGENTS FOR THE PREVENTION OR INHIBITION OF TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2011-11-24 WO claimed
CN-101712648-B Synthesis method of azepine anthraquinone NANJING UNIVERSITY OF TECHNOLOGY 2011-11-09 CN claimed
US-20110059972-A1 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-03-10 US claimed
EP-2257515-A1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF Centre National de la Recherche Scientifique (FR) 2010-12-08 EP claimed
CN-101712648-A Synthesis method of azepine anthraquinone NANJING UNIVERSITY OF TECHNOLOGY 2010-05-26 CN claimed
WO-2009118327-A1 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2009-10-01 WO claimed
JP-2003507363-A 2003-02-25 JP claimed
US-6515127-B1 The invention concerns a method for preparing quinoline-5,8-diones of formula (I) light-induced oxygenation of a 8-hydroxyquinoline. and intermediates LABORATOIRE L. LAFON (FR) 2003-02-04 US claimed
EP-1202972-A2 METHOD FOR PREPARING QUINOLINE-5,8-DIONES LABORATOIRE L. LAFON (FR) 2002-05-08 EP claimed
WO-2001012597-A2 METHOD FOR PREPARING QUINOLINE-5,8-DIONES LABORATOIRE L. LAFON (FR) 2001-02-22 WO claimed
EP-0519290-A1 Use of 6(7)-amino-substituted-5,8-quinolinediones to combat endoparasites, new 6(7)-aminosubstituted 5,8-quinolinediones and processes for their preparation BAYER AG (DE) 1992-12-23 EP claimed
EP-0251094-A2 Substituted quinoxalinediones and quinolinediones AMERICAN CYANAMID COMPANY (US) 1988-01-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS S100A4, S100A6, S100A10 S100A4 1/4885CDC25B 211/4885TDP2 4122/4885
US-20140194604-A1 PROCESS FOR THE SYNTHESIS OF KETONES FROM INTERNAL ALKENES FASN, NOTUM, DGAT2 S100A4 2853/4885CDC25B 2960/4885TDP2 3886/4885
US-20110059972-A1 1,4-NAPHTHOQUINONES DERIVATIVES AND THERAPEUTIC USE THEREOF NQO1, NDUFV2, RECQL S100A4 3370/4885CDC25B 576/4885TDP2 3226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.